“…Utilization of PET/CT has been shown to be beneficial in altering the management of patients compared to imaging with just CT or PET alone (Mavi et al, 2005). PET/CT is currently utilized in the diagnosis and staging of multiple malignancies (Carter and Kotlyarov, 2005). It is approved in the United States for the characterization of solitary pulmonary nodules, the diagnosis-stagingrestaging of colon carcinoma, lymphoma, melanoma, esophageal carcinoma, and head and neck cancers.…”
“…Utilization of PET/CT has been shown to be beneficial in altering the management of patients compared to imaging with just CT or PET alone (Mavi et al, 2005). PET/CT is currently utilized in the diagnosis and staging of multiple malignancies (Carter and Kotlyarov, 2005). It is approved in the United States for the characterization of solitary pulmonary nodules, the diagnosis-stagingrestaging of colon carcinoma, lymphoma, melanoma, esophageal carcinoma, and head and neck cancers.…”
“…Radiographs and scintigraphies may show an air fluid level in the gastric pouch, malposition, angulation of the band bands, problems with gastric emptying, and gastric obstruction (O'Brien et al, 2005). The radiopharmaceuticals are frequently used in diagnostic procedures (Bingener-Casey et al, 2002, Carter & Kotlyarov, 2005. Examinations of gastric emptying, patency of anastomoses, enterogastric reflux, hepatic and thyroid diseases, osteoporosis and metastasis, frequently are carried after bariatric surgery (Kitabaiashi et al, 2002;Fonseca et al, 2000;Badiali et al, 2001;Obradovic et al, 2000).…”
“…For historical reasons, PET studies initially focused on the brain and the heart. Now, PET is often used in oncologic indications (Carter and Kotlyarov, 2005). This development resulted from the use of fluorodeoxyglucose-(18F) or FDG, and from the successful application of FDG-(18F) PET to a growing number of important human cancers to solve clinical problems at varying stages of diagnosis, staging and follow-up.…”
Positron emission tomography (PET) and its recent update PET/CT are very effective diagnostic tools for non-invasive imaging of metabolic or functional disorders in target tissues. The clinical usefulness of fluorodeoxyglucose-(18F) (FDG) has been now widely accepted. Recently, the clinical usefulness of fluoroDOPA-(18F) or FDOPA, an aminoacid labelled with the same positron emitter fluorine-18, has been evaluated and recognised in France and subsequently in several EU countries. FDOPA is diagnostic PET agent, which has been used for decades in imaging the loss of dopaminergic neurons in Parkinson's disease, and more recently to detect, stage and restage neuroendocrine tumours and to search for recurrence of viable glioma tissue. The present article summarises the body of evidence that led the French Medicines Agency (AFSSAPS) to grant a marketing authorisation to IASOdopa, a commercial preparation of FDOPA. Brief case reports and figures illustrate the diagnostic performance of FDOPA PET or PET/CT in the different settings that are currently approved in oncology. Tomografia por emissão de positrons (PET) e sua recente atualização PET/CT são ferramentas de diagnóstico muito eficientes para imagens não invasivas de desordens metabólicas ou funcionais em tecido alvo. A utilidade clínica da fluordesoxiglicose-(18F)(FDG) tem sido agora largamente aceita. Recentemente, a utilidade clinica de fluoroDOPA-(18F) ou FDOPA, um aminoácido marcado com o mesmo emissor de pósitron, flúor-18, tem sido avaliado e reconhecido na França e subsequentemente em alguns países da União Européia. FDOPA é o radiofármaco para diagnóstico em PET, o qual tem sido usado por décadas para obtenção de imagens da perda de neurônios dopaminérgicos na doença de Parkinson e, mais recentemente, para identificar inicialmente o estágio e a reavaliação de tumores neuroendócrinos e para a pesquisa da recorrência de glioma viável. O presente artigo resume o conjunto de evidências que levarão a Agência Médica Francesa (AFSSAPS) garantir uma autorização de divulgação da IASOdopa, uma preparação comercial da FDOPA. O relato breve de caso e figuras que ilustram um padrão de imagem de diagnóstico usando FDOPA em PET ou PET/CT em diferentes configurações que são aceitas em oncologia
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.